| Schedule of financial instrument measured at fair value |
| Schedule of financial instrument measured at fair value | |
| | | |
| | | |
| | | |
| | |
| | |
Fair Value Measurement at June 30, 2022 | |
| | |
Total | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| Investment in term promissory note of Ault & Company, Inc. (“Ault & Company”) and other – a related party | |
$ | 2,770,000 | | |
$ | - | | |
$ | - | | |
$ | 2,770,000 | |
| Investment in common stock of Alzamend Neuro, Inc. (“Alzamend”) – a related party | |
| 8,845,000 | | |
| 8,845,000 | | |
| - | | |
| - | |
| Investments in marketable equity securities | |
| 17,467,000 | | |
| 17,467,000 | | |
| - | | |
| - | |
| Cash and marketable securities held in trust account | |
| 116,895,000 | | |
| 116,895,000 | | |
| - | | |
| - | |
| Investments in other equity securities | |
| 804,000 | | |
| - | | |
| - | | |
| 804,000 | |
| Total assets measured at fair value | |
$ | 146,781,000 | | |
$ | 143,207,000 | | |
$ | - | | |
$ | 3,574,000 | |
| | |
Fair Value Measurement at December 31, 2021 | |
| | |
Total | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| Investment in term promissory note of Ault & Company and other – a related party | |
$ | 2,842,000 | | |
$ | - | | |
$ | - | | |
$ | 2,842,000 | |
| Investment in common stock of Alzamend – a related party | |
| 13,230,000 | | |
| 13,230,000 | | |
| - | | |
| - | |
| Investments in marketable equity securities | |
| 40,380,000 | | |
| 40,380,000 | | |
| - | | |
| - | |
| Cash and marketable securities held in trust account | |
| 116,725,000 | | |
| 116,725,000 | | |
| - | | |
| - | |
| Investments in other equity securities | |
| 9,215,000 | | |
| - | | |
| - | | |
| 9,215,000 | |
| Total assets measured at fair value | |
$ | 182,392,000 | | |
$ | 170,335,000 | | |
$ | - | | |
$ | 12,057,000 | |
|
| Schedule of other equity securities measured and carried at fair value |
| Schedule of other equity securities measured and carried at fair value | |
| | |
| | |
Investments in
other equity
securities | |
| Balance at January 1, 2022 | |
$ | 9,215,000 | |
| Investment in preferred stock | |
| 2,550,000 | |
| Change in fair value of warrants | |
| 13,867,000 | |
| Conversion to marketable securities | |
| (24,828,000 | ) |
| Balance at June 30, 2022 | |
$ | 804,000 | |
|
| Schedule of investments not measured |
| Schedule of investments not measured | |
| | |
| | |
| | |
| |
| | |
Fair Value Measurement Using | |
| | |
Total | | |
Quoted prices
in active
markets for
identical assets
(Level 1) | | |
Other
observable
inputs
(Level 2) | | |
Significant
unobservable
inputs
(Level 3) | |
| As of June 30, 2022 | |
| | |
| | |
| | |
| |
| Investments in other equity securities that do not report net asset value | |
$ | 37,691,000 | | |
$ | - | | |
$ | - | | |
$ | 37,691,000 | |
| | |
Fair
Value Measurement Using | |
| | |
Total | | |
Quoted prices
in active
markets for
identical assets
(Level 1) | | |
Other
observable
inputs
(Level 2) | | |
Significant
unobservable
inputs
(Level 3) | |
| As of December 31, 2021 | |
| | | |
| | | |
| | | |
| | |
| Investments in other equity securities that do not report net asset value | |
$ | 21,241,000 | | |
$ | - | | |
$ | - | | |
$ | 21,241,000 | |
|